163 related articles for article (PubMed ID: 18069279)
1. [Bisphosphonates for myeloma patients].
Miwa A
Nihon Rinsho; 2007 Dec; 65(12):2315-37. PubMed ID: 18069279
[TBL] [Abstract][Full Text] [Related]
2. Osteonecrosis of the jaw in cancer after treatment with bisphosphonates: incidence and risk factors.
Bamias A; Kastritis E; Bamia C; Moulopoulos LA; Melakopoulos I; Bozas G; Koutsoukou V; Gika D; Anagnostopoulos A; Papadimitriou C; Terpos E; Dimopoulos MA
J Clin Oncol; 2005 Dec; 23(34):8580-7. PubMed ID: 16314620
[TBL] [Abstract][Full Text] [Related]
3. Osteonecrosis of the jaw correlated to bisphosphonate therapy in non-oncologic patients: clinicopathological features of 24 patients.
Favia G; Pilolli GP; Maiorano E
J Rheumatol; 2009 Dec; 36(12):2780-7. PubMed ID: 19884275
[TBL] [Abstract][Full Text] [Related]
4. Epidemiology and risk factors for osteonecrosis of the jaw in cancer patients.
Hoff AO; Toth B; Hu M; Hortobagyi GN; Gagel RF
Ann N Y Acad Sci; 2011 Feb; 1218():47-54. PubMed ID: 20946574
[TBL] [Abstract][Full Text] [Related]
5. [Multiple myeloma].
Abe M
Nihon Rinsho; 2009 May; 67(5):991-5. PubMed ID: 19432122
[TBL] [Abstract][Full Text] [Related]
6. [Bisphosphonates and osteonecrosis of the jaws].
Urade M
Clin Calcium; 2007 Feb; 17(2):241-8. PubMed ID: 17272882
[TBL] [Abstract][Full Text] [Related]
7. Bisphosphonate-associated osteonecrosis of the jaw: conclusions based on an analysis of case series.
Landesberg R; Wilson T; Grbic JT
Dent Today; 2006 Aug; 25(8):52, 54-7. PubMed ID: 16925161
[TBL] [Abstract][Full Text] [Related]
8. Osteonecrosis of the jaw in patients receiving intravenous or oral bisphosphonates.
King AE; Umland EM
Pharmacotherapy; 2008 May; 28(5):667-77. PubMed ID: 18447663
[TBL] [Abstract][Full Text] [Related]
9. Incidence of osteonecrosis of the jaw in patients with multiple myeloma and breast or prostate cancer on intravenous bisphosphonate therapy.
Wang EP; Kaban LB; Strewler GJ; Raje N; Troulis MJ
J Oral Maxillofac Surg; 2007 Jul; 65(7):1328-31. PubMed ID: 17577497
[TBL] [Abstract][Full Text] [Related]
10. A review of the literature on osteonecrosis of the jaw in patients with osteoporosis treated with oral bisphosphonates: prevalence, risk factors, and clinical characteristics.
Pazianas M; Miller P; Blumentals WA; Bernal M; Kothawala P
Clin Ther; 2007 Aug; 29(8):1548-58. PubMed ID: 17919538
[TBL] [Abstract][Full Text] [Related]
11. Safety profile of intravenous bisphosphonates.
Mehrotra B
Semin Oncol; 2007 Dec; 34(6 Suppl 4):S24-7. PubMed ID: 18068487
[TBL] [Abstract][Full Text] [Related]
12. Osteonecrosis of the jaw complicating bisphosphonate treatment for bone disease in multiple myeloma: an overview with recommendations for prevention and treatment.
Dickinson M; Prince HM; Kirsa S; Zannettino A; Gibbs SD; Mileshkin L; O'Grady J; Seymour JF; Szer J; Horvath N; Joshua DE
Intern Med J; 2009 May; 39(5):304-16. PubMed ID: 19220531
[TBL] [Abstract][Full Text] [Related]
13. [Osteonecrosis of the jaw associated with the use of bisphosphonates in multiple myeloma: report of four cases and literature review].
Li LH; Wu XB; Chen WM; Chen JX; Wu Y; Chen SL
Zhonghua Yi Xue Za Zhi; 2008 Nov; 88(42):2986-7. PubMed ID: 19080077
[TBL] [Abstract][Full Text] [Related]
14. The incidence of jaw osteonecrosis in multiple myeloma patients treated with bisphosphonates.
Kraj M; Pogłód R; Maj S; Owczarska K
Acta Pol Pharm; 2006; 63(5):450-2. PubMed ID: 17357613
[No Abstract] [Full Text] [Related]
15. Bisphosphonates and jaw osteonecrosis: the UAMS experience.
Clarke BM; Boyette J; Vural E; Suen JY; Anaissie EJ; Stack BC
Otolaryngol Head Neck Surg; 2007 Mar; 136(3):396-400. PubMed ID: 17321866
[TBL] [Abstract][Full Text] [Related]
16. Bisphosphonates induce apoptosis of circulating endothelial cells in multiple myeloma patients and in subjects with bisphosphonate-induced osteonecrosis of the jaws.
Allegra A; Alonci A; Penna G; Granata A; Nastro Siniscalchi E; Oteri G; Loddo S; Teti D; Cicciù D; De Ponte FS; Musolino C
Acta Haematol; 2010; 124(2):79-85. PubMed ID: 20639624
[TBL] [Abstract][Full Text] [Related]
17. Prevalence and risk factors of bisphosphonate-associated osteonecrosis of the jaw in prostate cancer patients with advanced disease treated with zoledronate.
Walter C; Al-Nawas B; Grötz KA; Thomas C; Thüroff JW; Zinser V; Gamm H; Beck J; Wagner W
Eur Urol; 2008 Nov; 54(5):1066-72. PubMed ID: 18602738
[TBL] [Abstract][Full Text] [Related]
18. "Bis-phossy jaws" - high and low risk factors for bisphosphonate-induced osteonecrosis of the jaw.
Abu-Id MH; Warnke PH; Gottschalk J; Springer I; Wiltfang J; Acil Y; Russo PA; Kreusch T
J Craniomaxillofac Surg; 2008 Mar; 36(2):95-103. PubMed ID: 18234504
[TBL] [Abstract][Full Text] [Related]
19. Osteonecrosis of the jaw and bisphosphonate use in breast cancer patients.
Kyrgidis A; Triaridis S; Vahtsevanos K; Antoniades K
Expert Rev Anticancer Ther; 2009 Aug; 9(8):1125-34. PubMed ID: 19671032
[TBL] [Abstract][Full Text] [Related]
20. [Osteonecrosis of the jaw and bisphophonates in oncology].
Facon T; Bensadoun RJ; Blanc JL; Confavreux C; Gourmet R; Maes JM; Penel G; Vieillard MH; Woeller A
Bull Cancer; 2008 Apr; 95(4):413-8. PubMed ID: 18495570
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
